

New Tests and Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, June 03, 2013

New Tests - Tests recently added to the NMS Labs test menu. New Tests are effective immediately.

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

Effective Date:

Monday, June 03, 2013



New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0615SP	Benzthiazide, Serum/Plasma									•
0796B	Bumetanide, Blood			•	•	•			•	
0796SP	Bumetanide, Serum/Plasma			•	•	•			•	
1180B	Chlorothiazide, Blood			•	•	•		•	•	
1180SP	Chlorothiazide, Serum/Plasma			•	•	•		•	•	
1250B	Chlorthalidone, Blood			•	•	•		•	•	
1250SP	Chlorthalidone, Serum/Plasma			•	•	•		•	•	
1411B	Cyclohexanone, Blood (CSA)									•
1515SP	Diazoxide, Serum/Plasma			•	•	•		•	•	
1804SP	Diuretics Panel, Serum/Plasma			•	•	•		•	•	
1900B	Dyazide, Blood			•	•	•		•	•	
1900SP	Dyazide, Serum/Plasma			•	•	•		•	•	
52155B	Furosemide Confirmation, Blood (Forensic) (CSA)			•	•	•		•	•	
52155SF	, Furosemide Confirmation, Serum/Plasma (Forensic) (CSA)			•	•	•		•	•	
52155U	Furosemide Confirmation, Urine (Forensic) (CSA)			•		•		•	•	
9545B	Furosemide Screen (Add-On), Blood (Forensic) (CSA)			•	•	•		•	•	
9545SP	Furosemide Screen (Add-On), Serum/Plasma (Forensic) (CSA)			•	•	•		•	•	
9545U	Furosemide Screen (Add-On), Urine (Forensic) (CSA)			•	•	•		•	•	
2140B	Furosemide, Blood			•	•	•		•	•	
2140SP	Furosemide, Serum/Plasma			•	•	•		•	•	
2140U	Furosemide, Urine			•		•		•	•	
9328U	Gamma-Hydroxybutyric Acid Screen, Urine (CSA)									•
52156B	Hydrochlorothiazide Confirmation, Blood (Forensic) (CSA)			•	•	•		•	•	
52156SF	, Hydrochlorothiazide Confirmation, Serum/Plasma (Forensic) (CSA)			•	•	•		•	•	
52156U	Hydrochlorothiazide Confirmation, Urine (Forensic) (CSA)			•				•	•	
9546B	Hydrochlorothiazide Screen (Add- On), Blood (Forensic) (CSA)			•	•	•		•	•	
9546SP	Hydrochlorothiazide Screen (Add- On), Serum/Plasma (Forensic) (CSA)			•	•	•		•	•	
9546U	Hydrochlorothiazide Screen (Add- On), Urine (Forensic) (CSA)			•	•			•	•	
2330B	Hydrochlorothiazide, Blood			•	•	•		•	•	

Effective Date:

Monday, June 03, 2013



New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
2330FL	Hydrochlorothiazide, Fluid									•
2330SP	Hydrochlorothiazide, Serum/Plasma			•	•	•		•	•	
2330TI	Hydrochlorothiazide, Tissue									•
2330U	Hydrochlorothiazide, Urine			•				•	•	
2345SP	Hydroflumethiazide, Serum/Plasma			•	•	•		•	•	
2397SP	Indapamide, Serum/Plasma	•								
2245B	Metal Implant Panel, Blood (CSA)									•
2865SP	Methazolamide, Serum/Plasma (CSA)									•
2953B	Methyclothiazide, Blood									•
2953SP	Methyclothiazide, Serum/Plasma									•
3042B	Metolazone, Blood			•	•	•		•	•	
3042SP	2SP Metolazone, Serum/Plasma			•	•	•		•	•	
3065SP	Mitotane, Serum/Plasma (CSA)									•
3093B	Molybdenum, Blood (CSA)									•
3433SP	Perampanel, Serum/Plasma	•								
4486B	Titanium, Blood				•					
4525B	Torsemide, Blood	•								
4525SP	Torsemide, Serum/Plasma	•								
5439B	Triamterene Confirmation, Blood									•
5439SP	Triamterene Confirmation, Serum/Plasma									•
9283B	Triamterene Screen, Blood									•
9283SP	Triamterene Screen, Serum/Plasma									•
4540B	Triamterene, Blood			•	•	•			•	
4540SP	Triamterene, Serum/Plasma			•	•	•			•	
4615B	Trichlormethiazide, Blood									•
4615SP	Trichlormethiazide, Serum/Plasma									•
4624U	Trichloroacetic Acid, Urine	•								
4627U	Trichloroacetic Acid, Urine									•



New Tests and Test Updates

New Tests

2397SP Indapamid	e, Serum/Plasma		Effective Immediately			
Scope of Analysis:	Indapamide [LC-MS/MS]					
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)					
Purpose:	Therapeutic Drug Monitoring. This tes	st is New York S	State approved.			
Category:	Antihypertensive, Diuretic					
Specimen Requirements:	1 mL Serum or Plasma					
Minimum Volume:	0.4 mL					
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.					
Specimen Container:	Plastic container (preservative-free)					
Transport Temperature:	Refrigerated					
Light Protection:	Not Required					
Rejection Criteria:	Polymer gel separation tube (SST or PST).					
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)					
Method: High (LC-I	Performance Liquid Chroma MS/MS)	tography/Ta	andem Mass Spectrometry			
Set-Up Days / TAT: Tuesd	ay Thursday 2 days (after set-up)					
CPT Code: 83789						
Compound Name / Alias	s Units	RL	Reference Comment			
Indapamide Lozol®	ng/mL	10	Normal subjects taking 2.5 mg daily normal release indapamide had steady state peak blood concentrations of 150 +/- 35 ng/mL. The blood to plasma ratio for indapamide is approximately 6.			
3433SP Perampan	el, Serum/Plasma		Effective Immediately			

Scope of Analysis: Perampanel [LC-MS/MS] High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) Method(s): Purpose: Therapeutic Drug Monitoring. This test is New York State approved. Anticonvulsant, Antiepileptic Category: Specimen Requirements: 1 mL Serum or Plasma Minimum Volume: 0.3 mL Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Plastic container (preservative-free) Specimen Container: Refrigerated Transport Temperature: Light Protection: Not Required Rejection Criteria: Polymer gel separation tube (SST or PST). Room Temperature: 1 month(s) Stability: Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)



Effective Immediately

New Tests and Test Updates

New Tests

Method:	High P (LC-M	erformance Liqu S/MS)	id Chromato	ography/Ta	andem Mass Spectrometry		
Set-Up Days / TAT:	Friday 2	days (after set-up)					
CPT Code:	83789						
Compound Name /	Alias		Units	RL	Reference Comment		
Perampanel Fycompa®			ng/mL	20	Daily administration of 6 mg perampanel resulted in peak plasma concentrations averaging 460 ng/mL at approximately 1.3 hours post dose. Peak concentrations following a single 12 mg dose of perampanel averaged 800 ng/mL.		
4525B Torsei	mide, E	Blood			Effective Immediately		
Scope of Anal	ysis: T	orsemide [LC-MS/MS]	l				
Metho	d(s): ⊦	ligh Performance Liqu	id Chromatogra	ohy/Tandem N	lass Spectrometry (LC-MS/MS)		
Purp	ose: T	herapeutic Drug Moni	toring. This test	is New York S	tate approved.		
Categ	gory: A	ntihypertensive, Diure	etic				
Specimen Requireme	ents: 1	mL Blood					
Minimum Volu	ume: 0	0.4 mL					
Special Hand	lling: N	None					
Specimen Conta	iner: L	avender top tube (ED	TA)				
Transport Tempera	ture: F	Refrigerated					
Light Protec	tion: N	lot Required					
Rejection Crit	eria: N	lone					
Stab	Dility: F F F	coom Temperature: 1 r cefrigerated: 1 month(s rozen (-20 °C): 1 mon	nonth(s) s) th(s)				
Method:	High P (LC-M	erformance Liqu S/MS)	id Chromato	ography/Ta	andem Mass Spectrometry		
Set-Up Days / TAT:	Tuesday	Thursday 2 days (afte	er set-up)				
CPT Code:	83789						
Compound Name /	Alias		Units	RL	Reference Comment		
Torsemide Demadex®; Torasemid	e		ng/mL	25	Chronic oral administration of 40 mg torsemide produced peak plasma concentrations ranging from 2800 - 3800 ng/mL. The blood to plasma ratio of torsemide is not known.		

4525SP Torsemide, Serum/Plasma

Scope of Analysis:	Torsemide [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Therapeutic Drug Monitoring. This test is New York State approved.
Category:	Antihypertensive, Diuretic
Specimen Requirements:	1 mL Serum or Plasma
Minimum Volume:	0.4 mL
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container:	Plastic container (preservative-free)

Effective Date:

Monday, June 03, 2013



New Tests and Test Updates

New Tests

Transport Temperature:	Refrigerated			
Light Protection:	Not Required			
Rejection Criteria:	Polymer gel separation tube (SST or	PST).		
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)			
Method: High (LC-I	Performance Liquid Chroma MS/MS)	tography/	Tandem Mass Spectrometry	
Set-Up Days / TAT: Tuesd	ay Thursday 2 days (after set-up)			
CPT Code: 83789				
Compound Name / Alias	s Units	RL	Reference Comment	
Torsemide Demadex®; Torasemide	ng/mL	25	Chronic oral administration of 40 mg torsemide produced peak plasma concentrations ranging from 2800 - 3800 ng/mL.	
4624U Trichloroad	cetic Acid, Urine		Effective Immedi	ately
Scope of Analysis:	Trichloroacetic Acid [GC]			
Method(s):	Gas Chromatography (GC)			
Purpose:	Occupational Exposure Monitoring, A	CGIH/BEI. T	his test is New York State approved.	
Category:	Environmental/Occupation Toxin			
Specimen Requirements:	1 mL Urine			
Minimum Volume:	0.4 mL			
Special Handling:	None			
Specimen Container:	Plastic container (preservative-free)			
Transport Temperature:	Refrigerated			
Light Protection:	Not Required			
Rejection Criteria:	None			
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)			
Method: Gas	Chromatography (GC)			
Set-Up Days / TAT: Wedne	esday 4 days (after set-up)			
CPT Code: 83921				

Compound Name / Alias	Units	RL	Reference Comment
Trichloroacetic Acid TCA; Trichloroacetate	mg/L	0.5	Biological Exposure Index (ACGIH): Following workplace exposure to Methyl Chloroform: 10 mg/L measured in an end of workweek urine specimen.
			15 mg/L measured in an end of shift at end of workweek urine specimen.



New Tests and Test Updates

Test Changes

0796B Bumetanide, B	Blood	
Summary of Changes:	Specimen Requirements were of Specimen Requirements (Speci Stability was changed. Reference Comment was change Methods/CPT Codes were changed	hanged. men Container) were changed. ged. ged [LC-MS/MS (83789)]
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Bumetanide	9
Compound Name	Units	Reference Comment
Bumetanide	ng/mL	Peak plasma concentrations were 97 +/- 15 ng/mL in eight healthy subjects following 2 mg and 180 +/- 100 ng/mL in four healthy subjects following 5 mg oral bumetanide. The blood to plasma ratio for bumetanide is not known.
0796SP Bumetanide, S	Serum/Plasma	
Summary of Changes:	Specimen Requirements were of Specimen Requirements (Speci Specimen Requirements (Speci Stability was changed. Reference Comment was change Methods/CPT Codes were chan	hanged. men Container) were changed. al Handling) were changed. ged. ged [LC-MS/MS (83789)]
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-f	ree)
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in Red to Plasma: Collect sample in Lave Promptly centrifuge and separat using approved guidelines.	op tube nder top tube (EDTA) or Pink top tube. e Serum or Plasma into a plastic screw capped vial
Rejection Criteria:	Polymer gel separation tube (SS	ST or PST).



New Tests and Test Updates

Test Changes

Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Bumetanic	le
Compound Name	Units	Reference Comment
Bumetanide	ng/mL	Peak plasma concentrations were 97 +/- 15 ng/mL in eight healthy subjects following 2 mg and 180 +/- 100 ng/mL in four healthy subjects following 5 mg oral bumetanide.
1180B Chlorothiazide	e, Blood	
Summary of Changes:	Specimen Requirements (Spec Stability was changed. Reference Comment was chan Units were changed. Methods/CPT Codes were chan	imen Container) were changed. ged. nged [LC-MS/MS (83789)]
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Chlorothia	zide
Compound Name	Units	Reference Comment
Chlorothiazide	ng/mL	Peak plasma levels following a single 500 mg oral dose of chlorothiazide were 400 - 900 ng/mL at approximately 1 to 2 hours post dose. The blood to plasma ratio for chlorothiazide is approximately 0.6

1180SP Chlorothiazide, Serum/Plasma



New Tests and Test Updates

Test Changes

	. (0 0000)	
Scope Method	e of Analysis: I (CPT Code)	Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Chlorothiazide
	Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s)
Rejec	ction Criteria:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).
Spec	cial Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube
Ligi	nt Protection:	Not Required
Specime	en Container:	Plastic container (preservative-free)
Transport ⁻	Temperature:	Refrigerated
Specimen R	equirements:	1 mL Serum or Plasma
Summary	of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]

Compound Name	Units	Reference Comment
Chlorothiazide	ng/mL	Peak plasma levels following a single 500 mg oral dose of chlorothiazide were 400 - 900 ng/mL at approximately 1 to 2 hours post dose.

1250B Chlorthalidone, Blood

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)



New Tests and Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (83789): Chlorthalidone Method (CPT Code)

Compound Name	Units	Reference Comment
Chlorthalidone	ng/mL	Peak plasma concentrations following chronic 50 mg oral administration of chlorthalidone ranged from 280 - 1400 ng/mL (average 710 ng/mL). The blood to plasma ratio of chlorthalidone is concentration dependent and ranges from 10 to 30.
250SP Chlorthalidone	e, Serum/Plasma	
Summary of Changes:	Specimen Requirements were Specimen Requirements (Spe Specimen Requirements (Spe Stability was changed. Reference Comment was cha Units were changed. Methods/CPT Codes were ch	e changed. ecimen Container) were changed. ecial Handling) were changed. nged. anged [LC-MS/MS (83789)]
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST)	
Scope of Analysis:	Room Temperature: 1 month(Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Chlorthal	s) idone
	11-24-	Defense Original
Compound Name	Units	Reference Comment
Chlorthalidone	ng/mL	Peak plasma concentrations following chronic 50 mg oral administration of chlorthalidone ranged from 280 - 1400 ng/mL (average 710 ng/mL).

1515SP Diazoxide, Serum/Plasma



New Tests and Test Updates

Test Changes

Compound Name	Unito	Beference Comment
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Diazoxide	
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)	
Rejection Criteria:	Polymer gel separation tube (S	51 or PS1).
Special Handling:	Serum: Collect sample in Red to Plasma: Collect sample in Lave Promptly centrifuge and separa using approved guidelines.	op tube nder top tube (EDTA) or Pink top tube. te Serum or Plasma into a plastic screw capped vial
Light Protection:	Not Required	
Specimen Container:	Plastic container (preservative-f	ree)
Transport Temperature:	Refrigerated	
Specimen Requirements:	1 mL Serum or Plasma	
Summary of Changes:	Specimen Requirements were of Specimen Requirements (Speci Specimen Requirements (Speci Stability was changed. Reference Comment was change Units were changed. Methods/CPT Codes were char	changed. imen Container) were changed. ial Handling) were changed. ged. nged [LC-MS/MS (83789)]

Compound Name	Units	Reference Comment
Diazoxide	ng/mL	Plateau plasma concentrations following 300 mg intravenous injection of diazoxide ranged from 15000 - 25000 ng/mL.

1804SP Diuretics Panel, Serum/Plasma

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]
---------------------	--



New Tests and Test Updates

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Chlorothiazide, Hydrochlorothiazide, Furosemide

Compound Name	Units	Reference Comment
Chlorothiazide	ng/mL	Peak plasma levels following a single 500 mg oral dose of chlorothiazide were 400 - 900 ng/mL at approximately 1 to 2 hours post dose.
Hydrochlorothiazide	drochlorothiazide ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.
Furosemide	ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects.
900B Dyazide, Blood	b	
Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Units were changed.	



New Tests and Test Updates

The blood to plasma ratio for hydrochlorothiazide is

Chronic oral administration of 75 mg triamterene in combination with 50 mg hydrochlorothiazide resulted in peak plasma concentrations of 200 +/- 130 ng/mL

The blood to plasma ratio for triamterene is

Test Changes

Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)	
Scope of Analysis:	LC-MS/MS (83789): Hydrochlo	prothiazide, Triamterene
Method (CPT Code)		
Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.

approximately 2.

triamterene.

approximately 1.

1900SP	Dyazide, Serum/Plasma	

ng/mL

Specimen Requirements (Sp Specimen Requirements (Sp Stability was changed. Reference Comment was ch Units were changed. Methods/CPT Codes were ch	anged [LC-MS/MS (83789)]
--	--------------------------

Triamterene



New Tests and Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Triamterene, Hydrochlorothiazide

Compound Name	Units	Reference Comment
Triamterene	ng/mL	Chronic oral administration of 75 mg triamterene in combination with 50 mg hydrochlorothiazide resulted in peak plasma concentrations of 200 +/- 130 ng/mL triamterene.
Hydrochlorothiazide ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:	
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.

52155B Furosemide Confirmation, Blood (Forensic) (CSA)

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Stability was changed.
	Reference Comment was changed.
	Units were changed.
	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Spacimon Doquiromonto	1 ml Blood

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None



New Tests and Test Updates

Test Changes

Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Furosemide

Compound Name	Units	Reference Comment
Furosemide	ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were
		obtained approximately 1 hour after a single oral dose
		of 80 mg furosemide in fasting subjects.
		The blood to plasma ratio of furosemide is not known.

52155SP Furosemide Confirmation, Serum/Plasma (Forensic) (CSA)

Summary of Changes:	Specimen Requirements (Spec	amen Container) were changed. Jal Handling) were changed.	
	Stability was changed.		
	Reference Comment was chan	ged.	
	Methods/CPT Codes were char	nged [LC-MS/MS (83789)]	
Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-	free)	
Light Protection:	Not Required		
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.		
Rejection Criteria:	Polymer gel separation tube (SST or PST).		
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Furosemic	le	
Compound Name	Units	Reference Comment	
Furosemide	ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were	

Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects.

52155U Furosemide Confirmation, Urine (Forensic) (CSA)

Summary of Changes: Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]

Effective Date:

Monday, June 03, 2013



New Tests and Test Updates

Test	Changes	
------	---------	--

Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 28 day(s) LC-MS/MS (83789): Furosemid	e
Compound Name	Units	Reference Comment
Furosemide	ng/mL	A peak urine concentration of 16000 ng/mL was reported in a healthy volunteer at 8 hours following a single 40 mg oral dose of furosemide.
9545B Furosemide S	creen (Add-On), Blood (Forens	ic) (CSA)
Summary of Changes:	Specimen Requirements (Spec Stability was changed. Reference Comment was chang Units were changed. Methods/CPT Codes were char	imen Container) were changed. ged. nged [LC-MS/MS (80100)]
Specimen Requirements:	2 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) LC-MS/MS (80100): Furosemid	e
Compound Name	Units	Reference Comment
Furosemide	ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects. The blood to plasma ratio of furosemide is not known.
9545SP Furosemide S	creen (Add-On), Serum/Plasma	(Forensic) (CSA)
Summary of Changes:	les: Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed.	

Methods/CPT Codes were changed [LC-MS/MS (80100)]

Reference Comment was changed.

Units were changed.

Effective Date:

Monday, June 03, 2013



New Tests and Test Updates

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST)
Scope of Analysis:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)
Method (CPT Code)	

Compound Name	Units	Reference Comment
Furosemide	ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects.

545U Furosemide S	creen (Add-On), Urine (Forensi	c) (CSA)
Summary of Changes:	Specimen Requirements were of Specimen Requirements (Speci Stability was changed. Reference Comment was change Units were changed. Methods/CPT Codes were char	changed. imen Container) were changed. ged. nged [LC-MS/MS (80100)]
Specimen Requirements:	2 mL Urine	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 28 day(s) LC-MS/MS (80100): Furosemid	e
Compound Name	Units	Reference Comment
Furosemide	ng/mL	A peak urine concentration of 16000 ng/mL was reported in a healthy volunteer at 8 hours following a single



New Tests and Test Updates

Test Changes

2140B Furosemide, B	lood	
Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]	
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) LC-MS/MS (83789): Furosemide	
Compound Name	Units	Reference Comment
Furosemide	ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects. The blood to plasma ratio of furosemide is not known.
2140SP Furosemide, S	erum/Plasma	
Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]	
Specimen Requirements:	1 ml. Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-	ree)
Light Protection:	Not Required	
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).	



New Tests and Test Updates

Scope of Method (C	Stability: Analysis: PT Code)	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Furosemid	e
Compound Nam	ne	Units	Reference Comment
Furosemide		ng/mL	Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects.
2140U Furo	semide, U	rine	
Summary of	Changes:	Stability was changed. Reference Comment was chang Units were changed. Methods/CPT Codes were char	ged. nged [LC-MS/MS (83789)]
Seene of	Stability:	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 28 day(s)	
Method (C	PT Code)	LC-INS/INS (83789): Furosemia	e
Compound Nam	ne	Units	Reference Comment
Furosemide		ng/mL	A peak urine concentration of 16000 ng/mL was reported in a healthy volunteer at 8 hours following a single 40 mg oral dose of furosemide.
52156B Hydr	rochloroth	iazide Confirmation, Blood (Fo	orensic) (CSA)
Summary of	Changes:	Specimen Requirements (Spec Stability was changed. Reference Comment was chang Units were changed. Methods/CPT Codes were char	imen Container) were changed. ged. nged [LC-MS/MS (83789)]
Specimen Requ Transport Tem Specimen C Light P Special Rejection	irements: operature: Container: Protection: Handling: n Criteria: Stability:	1 mL Blood Refrigerated Lavender top tube (EDTA) Not Required None None Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)	



New Tests and Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (83789): Hydrochlorothiazide Method (CPT Code)

Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.
		The blood to plasma ratio for hydrochlorothiazide is approximately 2.
52156SP Hydrochloroth	iazide Confirmation, Serun	n/Plasma (Forensic) (CSA)
Summary of Changes:	Specimen Requirements we Specimen Requirements (S Stability was changed. Reference Comment was c Units were changed. Methods/CPT Codes were c	ere changed. pecimen Container) were changed. hanged. changed [LC-MS/MS (83789)]
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservat	ive-free)
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in R Plasma: Collect sample in L Promptly centrifuge and ser using approved guidelines.	ed top tube .avender top tube (EDTA) or Pink top tube. parate Serum or Plasma into a plastic screw capped vial
Rejection Criteria:	Polymer gel separation tube	∋ (SST or PST).
Stability:	Room Temperature: 7 day(s Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)	s))
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Hydrochlorothiazide	



New Tests and Test Updates

Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = $34 + - 17$ ng/mL trough and 200 + - 93 ng/mL 5 hours post dose.
52156U Hydrochloroth	iazide Confirmation, Urine (Fo	rensic) (CSA)
Summary of Changes:	Reference Comment was chan Units were changed. Methods/CPT Codes were chan	ged. nged [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Hydrochlo	rothiazide
Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	A single 25 mg dose of hydrochlorothiazide produced a peak urinary concentration of 19000 ng/mL of the parent compound.
9546B Hydrochloroth	iazide Screen (Add-On), Blooc	I (Forensic) (CSA)
Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80100)]	
Specimen Requirements:	2 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80100): Hydrochlo	rothiazide



New Tests and Test Updates

Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = $34 + - 17$ ng/mL trough and 200 + - 93 ng/mL 5 hours post dose.
		The blood to plasma ratio for hydrochlorothiazide is approximately 2.
9546SP Hydrochloroth	niazide Screen (Add-On), Serur	n/Plasma (Forensic) (CSA)
Summary of Changes:	Specimen Requirements were Specimen Requirements (Spec Specimen Requirements (Spec Stability was changed. Reference Comment was chan Units were changed. Methods/CPT Codes were chan	changed. imen Container) were changed. ial Handling) were changed. ged. nged [LC-MS/MS (80100)]
Specimen Requirements:	2 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-	free)
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in Red t Plasma: Collect sample in Lave Promptly centrifuge and separa using approved guidelines.	op tube ender top tube (EDTA) or Pink top tube. ite Serum or Plasma into a plastic screw capped vial
Rejection Criteria:	Polymer gel separation tube (S	ST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s)	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80100): Hydrochlo	rothiazide



New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.
9546U Hydrochloroth	iazide Screen (Add-On),	Urine (Forensic) (CSA)
Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80100)]	
Specimen Requirements:	2 mL Urine	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80100): Hyd	Irochlorothiazide
Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	A single 25 mg dose of hydrochlorothiazide produced a peak urinary concentration of 19000 ng/mL of the parent compound.
2330B Hydrochloroth	iazide, Blood	

Summary of Changes:	Specimen Requirements (Specimen Container) were changed.
	Stability was changed.
	Reference Comment was changed.
	Units were changed.
	Methods/CPT Codes were changed [LC-MS/MS (83789)]



New Tests and Test Updates

Test Changes

Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Hydrochlc	prothiazide
Method (CPT Code)		
Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients: 25 mg = 17 + -8 ng/mL trough and $76 + -26 \text{ ng/mL}$ 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.
		The blood to plasma ratio for hydrochlorothiazide is approximately 2.
2330SP Hydrochlorot	hiazide, Serum/Plasma	

Summary of Changes:	Specimen Requirements were changed.
	Specimen Requirements (Specimen Container) were changed.
	Specimen Requirements (Special Handling) were changed.
	Stability was changed.
	Reference Comment was changed.
	Units were changed.
	Methods/CPT Codes were changed [LC-MS/MS (83789)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).

.



New Tests and Test Updates

Test Changes Stability: Room Temperature: 7 day(s)

Scope of Analysis: Method (CPT Code)	Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Hydrochlor	rothiazide
Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:
		25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose
		75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.
2330U Hydrochloroth	iazide, Urine	
Summary of Changes:	Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Hydrochlo	rothiazide
Compound Name	Units	Reference Comment
Hydrochlorothiazide	ng/mL	A single 25 mg dose of hydrochlorothiazide produced a peak urinary concentration of 19000 ng/mL of the parent compound.
2345SP Hydroflumethia	azide, Serum/Plasma	
Summary of Changes:	 Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. 	

Methods/CPT Codes were changed [LC-MS/MS (83789)]

Units were changed.



New Tests and Test Updates

Compound Namo	Unite	Potoronco Commont
Scope of Analysis: Method (CPT Code)	Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Hydroflun	nethiazide
Stability:	Room Temperature: 7 day(s)	
Rejection Criteria:	Plasma: Collect sample in Law Promptly centrifuge and separ using approved guidelines. Polymer gel separation tube (S	ender top tube (EDTA) or Pink top tube. ate Serum or Plasma into a plastic screw capped vial SST or PST).
Special Handling:	Serum: Collect sample in Red	top tube
Light Protection:	Not Required	
Specimen Container:	Plastic container (preservative	-free)
Transport Temperature:	Refrigerated	
Specimen Requirements:	1 mL Serum or Plasma	

Compound Name	Units	Reference Comment
Hydroflumethiazide	ng/mL	Peak plasma concentrations averaged 530 +/- 150 ng/mL in 6 healthy subjects taking 100 mg daily hydroflumethiazide for seven days.

Metolazone,	Blood	
Summary of Changes	: Specimen Requirements (Spec Stability was changed. Reference Comment was chan Units were changed. Methods/CPT Codes were cha	cimen Container) were changed. ged. nged [LC-MS/MS (83789)]
Specimen Requirements	: 1 mL Blood	
Transport Temperature	: Refrigerated	
Specimen Container	: Lavender top tube (EDTA)	
Light Protection	: Not Required	
Special Handling	: None	
Rejection Criteria	: None	
Stability Scope of Analysis Method (CPT Code	 Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Metolazon 	e
Compound Name	Units	Reference Comment
Metolazone	ng/mL	Peak blood concentrations averaged 70 ng/mL following a single 7.5 mg oral dose of metolazone in 6 healthy subjects.

LABS

Effective Date: Monday, June 03, 2013

New Tests and Test Updates

Test Changes

3042SP Metolazone, Se	erum/Plasma	
Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]	
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Metolazone	· •
	Unite	Poforonco Commont

Compound Name	Units	Reference Comment
Metolazone	ng/mL	Peak blood concentrations averaged 70 ng/mL following a single 7.5 mg oral dose of metolazone in 6 healthy subjects. The blood to plasma ratio for metolazone is approximately 0.8 to 1.

4486B Titanium, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Royal Blue top tube (Trace metal-free; EDTA)
Light Protection:	Not Required
Special Handling:	Clotted Blood specimens are not acceptable. Submit in container with a non-Heparin based anticoagulant. Tubes containing Heparin based anticoagulants are not acceptable.
Rejection Criteria:	Light Green top tube (Lithium Heparin). Tan top tube - glass (Sodium Heparin). Royal Blue top tube (Trace metal-free; Sodium Heparin). Green top tube (Sodium Heparin).



New Tests and Test Updates

4540B Triamterene, B	Blood	
Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]	
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 1 month(s) LC-MS/MS (83789): Triamtered	ne
Compound Name	Units	Reference Comment
Triamterene	ng/mL	Chronic oral administration of 75 mg triamterene in combination with 50 mg hydrochlorothiazide resulted in peak plasma concentrations of 200 +/- 130 ng/mL triamterene. The blood to plasma ratio for triamterene is approximately 1.
4540SP Triamterene, S	Serum/Plasma	
Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]	

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).



New Tests and Test Updates

Test Changes

mpound Name	Units	Reference Comment	
Method (CPT Code)			
Scope of Analysis:	LC-MS/MS (83789): Triamterene	e	
	Frozen (-20 °C): 1 month(s)		
	Refrigerated: 1 month(s)		
Stability:	Room Temperature: 1 month(s)		

 Compound Name
 Units
 Reference Comment

 Triamterene
 ng/mL
 Chronic oral administration of 75 mg triamterene in combination with 50 mg hydrochlorothiazide resulted in peak plasma concentrations of 200 +/- 130 ng/mL triamterene.



New Tests and Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
0615SP	Benzthiazide, Serum/Plasma	No Alternate Tests Available
1411B	Cyclohexanone, Blood (CSA)	No Alternate Tests Available
9328U	Gamma-Hydroxybutyric Acid Screen, Urine (CSA)	No Alternate Tests Available
2330FL	Hydrochlorothiazide, Fluid	2330B - Hydrochlorothiazide, Blood
		2330SP - Hydrochlorothiazide, Serum/Plasma
		2330U - Hydrochlorothiazide, Urine
2330TI	Hydrochlorothiazide, Tissue	2330B - Hydrochlorothiazide, Blood
		2330SP - Hydrochlorothiazide, Serum/Plasma
		2330U - Hydrochlorothiazide, Urine
2245B	Metal Implant Panel, Blood (CSA)	No Alternate Tests Available
2865SP	Methazolamide, Serum/Plasma (CSA)	No Alternate Tests Available
2953B	Methyclothiazide, Blood	2953U - Methyclothiazide, Urine
2953SP	Methyclothiazide, Serum/Plasma	2953U - Methyclothiazide, Urine
3065SP	Mitotane, Serum/Plasma (CSA)	No Alternate Tests Available
3093B	Molybdenum, Blood (CSA)	No Alternate Tests Available
5439B	Triamterene Confirmation, Blood	No Alternate Tests Available
5439SP	Triamterene Confirmation, Serum/Plasma	No Alternate Tests Available
9283B	Triamterene Screen, Blood	4540B - Triamterene, Blood
9283SP	Triamterene Screen, Serum/Plasma	4540SP - Triamterene, Serum/Plasma
4615B	Trichlormethiazide, Blood	4615U - Trichlormethiazide, Urine
4615SP	Trichlormethiazide, Serum/Plasma	4615U - Trichlormethiazide, Urine
4627U	Trichloroacetic Acid, Urine	4624U - Trichloroacetic Acid, Urine